Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)

Inclusion Criteria: * At least 18 years old at the time of their first (index) injection of brolucizumab. * Had documented neovascular age-related macular degeneration (nAMD) on or within 3 years before the index injection. * Used only brolucizumab for at least 12 months (± 45 days) after the index injection, with at least 1 brolucizumab injection given within the first 6 months after the index injection and at least 1 additional brolucizumab injection given at 6-12 months after the index injection. Exclusion Criteria: * Had received any other anti-VEGF agent between the index injection and 12-month follow-up. * Lacked information about the laterality of disease at the time of the index injection. * Lacked visual acuity assessments on or within 30 days before the index injection or at 6, 9, and 12 months after the index injection (all of the latter ± 45 days).